Article: DepoMed Raises $20M Privately For Metformin, Other Products.

Associate Managing Editor

DepoMed Inc. raised $20 million privately and will use the funds for clinical trials of multiple products, as well as to give it muscle in partnering talks.

DepoMed, of Menlo Park, Calif., sold 9.3 million shares at $2.16 to accredited investors. The price represents the average closing price of DepoMed's common stock for the 10 days preceding the closing of the financing. Investors also received 3.2 million common stock warrants exercisable for five years at the same price. If all warrants were exercised, the financing would total about $26.9 million.

DepoMed's stock (AMEX:DMI) rose 27 cents Tuesday, or 10.8 percent, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!